<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003956</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067155</org_study_id>
    <secondary_id>MSKCC-99020</secondary_id>
    <secondary_id>SPRI-C98-564-01</secondary_id>
    <secondary_id>NCI-G99-1540</secondary_id>
    <nct_id>NCT00003956</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Cancer</brief_title>
  <official_title>A Phase I Study of Continuous Oral Administration of SCH 66336 and 5-Fluorouracil/Leucovorin (5FU/LV) in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of SCH 66336, fluorouracil, and leucovorin&#xD;
      in treating patients who have advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety, tolerability, maximum tolerated dose, and dose limiting&#xD;
      toxicity of oral SCH 66336 with fluorouracil and leucovorin calcium in patients with advanced&#xD;
      malignancy. II. Assess the multiple dose pharmacokinetics of oral SCH 66336 when administered&#xD;
      with fluorouracil and leucovorin calcium. III. Assess the pharmacokinetics of fluorouracil&#xD;
      when administered with oral SCH 66336. IV. Assess antitumor activity of oral SCH 66336 with&#xD;
      fluorouracil and leucovorin calcium in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of SCH 66336. Patients receive oral SCH 66336 twice&#xD;
      daily for 56 days. Patients receive leucovorin calcium IV over 1-2 minutes immediately&#xD;
      followed by fluorouracil IV over 1-2 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat&#xD;
      every 56 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6&#xD;
      patients receive escalating doses of SCH 66336. The maximum tolerated dose is defined as the&#xD;
      dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during&#xD;
      course 1, with at least 2 patients experiencing DLT at the next higher level.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">January 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Lymphoma</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lonafarnib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven malignancy for which no curative therapy&#xD;
        exists At least 1 bidimensionally measurable lesion No acute or chronic leukemia or&#xD;
        multiple myeloma No active CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG-WHO 0-2 Life expectancy:&#xD;
        At least 12 weeks Hematopoietic: Absolute neutrophil count greater than 1,500/mm3 Platelet&#xD;
        count at least 100,000/mm3 Hemoglobin at least 9.0 g/dL Hepatic: Bilirubin no greater than&#xD;
        2.0 mg/dL SGOT or SGPT no greater than 3 times upper limit of normal (ULN) (5 times ULN if&#xD;
        elevations due to liver metastasis) Renal: Creatinine no greater than 1.5 times ULN&#xD;
        Cardiovascular: No prior or concurrent QTc interval prolongation greater than 500 m/sec,&#xD;
        unless approved by cardiology consult prior to study Other: No malabsorption syndrome due&#xD;
        to surgery, prior disease, or other unknown reason No frequent vomiting or other medical&#xD;
        condition that could interfere with oral medicine intake (e.g., partial bowel obstruction,&#xD;
        external biliary diversion) No concurrent nonmalignant systemic disease making patient a&#xD;
        poor risk for study No active uncontrolled infection Not pregnant or nursing Negative&#xD;
        pregnancy test Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior biologic therapy&#xD;
        and recovered No prior allogeneic, syngeneic, or autologous bone marrow transplantation No&#xD;
        prior peripheral blood stem cell transplantation No concurrent biologic therapy&#xD;
        Chemotherapy: No more than 2 prior chemotherapy regimens At least 4 weeks since prior&#xD;
        chemotherapy (6 weeks since mitomycin or nitrosoureas) and recovered No other concurrent&#xD;
        chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior&#xD;
        radiotherapy and recovered No prior wide field radiation (radiotherapy to at least 25% of&#xD;
        bone marrow, including pelvic irradiation) No concurrent radiotherapy Surgery: Prior major&#xD;
        gastrointestinal surgery allowed if recovered Other: At least 4 weeks since other prior&#xD;
        investigational therapy and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard B. Saltz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>September 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2004</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

